Molecular mechanism of edema formation in nephrotic syndrome;Mécanismes physiologiques et moléculaires de la constitution des œdèmes au cours du syndrome néphrotique

Archives de Pediatrie

Volumn 11, Issue 9, 2004, Pages 1084-1094

  Deschenes G ^a   Guigonis, V ^a   Doucet, A ^b  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Child; Edema, physiopathology; Nephrotic syndrome; Syndrome n phrotique; d mes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALDOSTERONE; AMILORIDE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; SODIUM CHANNEL; SPIRONOLACTONE; VASOPRESSIN;

CAPILLARY WALL; CLINICAL FEATURE; DRUG EFFECT; EDEMA; EXTRACELLULAR SPACE; FLUID TRANSPORT; HUMAN; HYDRAULIC CONDUCTIVITY; HYDROSTATIC PRESSURE; KIDNEY COLLECTING TUBULE; MOLECULAR MECHANICS; NATRIURESIS; NEPHROTIC SYNDROME; ONCOTIC PRESSURE; REVIEW; SODIUM ABSORPTION; SODIUM RETENTION; STARLING LAW;

EID: 4544333870     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2004.03.029     Document Type: Short Survey

References (72)

1. Morel F., Doucet A. Functional segmentation of the nephron. Seldin D., Giebisch G. The Kidney: Physiology and Pathophysiology. 1992;1049-1086 Raven Press Ltd, New York
2. Ichikawa I., Rennke H.G., Hoyer J.R., Badr K.F., Schor N., Troy J.L., et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest. 71:1983;91-103
3. Deschenes G., Wittner M., Stefano A., Jounier S., Doucet A. Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. J Am Soc Nephrol. 12:2001;598-601
4. Lourdel S., Zecevic M., Paulais M., Teulon J., Verrey F., Doucet A., et al. ENaC activation in experimental nephrotic syndrome. J Am Soc Nephrol. 12:2001;138A. (abstract)
5. +)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J Am Soc Nephrol. 11:2000;604-615
6. Feraille E., Vogt B., Rousselot M., Barlet-Bas C., Cheval L., Doucet A., et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest. 91:1993;1295-1300
7. +-ATPase activity and hormones in single nephron segments from nephrotic rats. Clin Sci (Lond). 80:1991;599-604
8. Deschenes G., Gonin S., Zolty E., Cheval L., Rousselot M., Martin P.Y., et al. Increased synthesis and avp unresponsiveness of Na,K-ATPase in collecting duct from nephrotic rats. J Am Soc Nephrol. 12:2001;2241-2252
9. Perico N., Delaini F., Lupini C., Benigni A., Galbusera M., Boccardo P., et al. Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney Int. 36:1989;57-64
10. Rabelink A.J., Koomans H.A., Gaillard C.A., Dorhout Mees E.J. Renal response to atrial natriuretic peptide in nephrotic syndrome. Nephrol Dial Transplant. 2:1987;510-514
11. Valentin J.P., Ying W.Z., Couser W.G., Humphreys M.H. Extrarenal resistance to atrial natriuretic peptide in rats with experimental nephrotic syndrome. Am J Physiol. 274:1998;F556-F563
12. Margulies K.B., Barclay P.L., Burnett J.C. Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 91:1995;2036-2042
13. Ni X.P., Safai M., Gardner D.G., Humphreys M.H. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int. 59:2001;1264-1273
14. Epstein A. Concerning the causation of edema in chronic parenchymatous nephritis: methods for its alleviation. Am J Med. 13:1952;556-561
15. Oliver W.J. Physiologic responses associated with steroid-induced diuresis in nephrotic syndrome. J Lab Clin Med. 62:1963;449-464
16. Lecomte J., Juchmès J. Sur la prétendue absence d'œdème chez les analbuminémiques. Rev Med Liège. 33:1978;766-770
17. Joles J.A., Willekes-Koolschijn N., Braam B., Kortlandt W., Koomans H.A., Dorhout Mees E.J. Colloid osmotic pressure in young analbuminemic rats. Am J Physiol. 257:1989;F23-F28
18. Deschenes G., Doucet A. Aldosterone does not influence urinary sodium excretion in PAN nephrosis. J Am Soc Nephrol. 12:2001;134A. (Abs A0704)
19. Vande Walle J., Donckerwolcke R., Boer P., Van Isselt H.W., Koomans H.A., Joles J.A. Blood volume, colloid osmotic pressure and F-cell ratio in children with the nephrotic syndrome. Kidney Int. 49:1996;1471-1477
20. Radin M.J., McCune S.A. The effect of atrial natriuretic peptide infusion on renal haemodynamics and plasma lipoproteins in puromycin aminonucleoside nephrosis in rats. Clin Exp Pharmacol Physiol. 20:1993;245-251
21. Kaysen G.A., Paukert T.T., Menke D.J., Couser W.G., Humphreys M.H. Plasma volume expansion is necessary for edema formation in the rate with Heymann nephritis. Am J Physiol. 248:1985;F247-F253
22. Geers A.B., Koomans H.A., Boer P., Dorhout Mees E.J. Plasma and blood volumes in patients with the nephrotic syndrome. Nephron. 38:1984;170-173
23. Tsau Y.K., Chen C.H., Tsai W.S., Sheu J.N. Complications of nephrotic syndrome in children. J Formos Med Assoc. 90:1991;555-559
24. Vande Walle J.G., Donckerwolcke R.A., Van Isselt J.W., Derkx F.H., Joles J.A., Koomans H.A. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet. 346:1995;148-152
25. Saatci U., Ozen S., Ozdemir S., Aras T. Atrial natriuretic peptide in childhood nephrotic syndrome. Nephrol Dial Transplant. 11:1996;905
26. Usberti M., Gazzotti R.M. Hyporeninemic hypoaldosteronism in patients with nephrotic syndrome. Am J Nephrol. 18:1998;251-255
27. Brown E.A., Markandu N.D., Sagnella G.A., Jones B.E., MacGregor G.A. Lack of effect of captopril on the sodium retention of the nephrotic syndrome. Nephron. 37:1984;43-48
28. Akcicek F., Yalniz T., Basci A., Ok E., Mees E.J. Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? BMJ. 310:1995;162-163
29. Na K.Y., Han J.S., Kim Y.S., Ahn C., Kim S., Lee J.S., et al. Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? J Korean Med Sci. 16:2001;448-454
30. Tulassay T., Rascher W., Lang R.E., Seyberth H.W., Scharer K. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int. 31:1987;1391-1395
31. Fliser D., Zurbruggen I., Mutschler E., Bischoff I., Nussberger J., Franek E., et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 55:1999;629-634
32. Sjostrom P.A., Odlind B.G. Effect of albumin on diuretic treatment in the nephrotic syndrome. BMJ. 310:1995;1537
33. Koomans H.A., Geers A.B., Meiracker A.H., Roos J.C., Boer P., Dorhout Mees E.J. Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome. Am J Nephrol. 4:1984;227-234
34. Trachtman H., Gauthier B. Platelet vasopressin levels in childhood idiopathic nephrotic syndrome. Am J Dis Child. 142:1988;1313-1316
35. Pyo H.J., Summer S.N., Niederberger M., Kim J.K., Schrier R.W. Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome. Am J Kidney Dis. 25:1995;58-62
36. Gonin S., Deschenes G., Roger F., Bens M., Martin P.Y., Carpentier J.L., et al. Cyclic AMP increases cell surface expression of functional Na,K-ATPase units in mammalian cortical collecting duct principal cells. Mol Biol Cell. 12:2001;255-264
37. Djelidi S., Fay M., Cluzeaud F., Escoubet B., Eugene E., Capurro C., et al. Transcriptional regulation of sodium transport by vasopressin in renal cells. J Biol Chem. 272:1997;32919-32924
38. Chabardes-Garonne D., Mejean A., Aude J.C., Cheval L., Di Stefano A., Gaillard M.C., et al. A panoramic view of gene expression in the human kidney. Proc Natl Acad Sci USA. 100:2003;13710-13715
39. Holzman L.B., St John P.L., Kovari I.A., Verma R., Holthofer H., Abrahamson D.R. Nephrin localizes to the slit pore of the glomerular epithelial cell. Kidney Int. 56:1999;1481-1491
40. Yang Y., Jeanpierre C., Dressler G.R., Lacoste M., Niaudet P., Gubler M.C. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol. 154:1999;181-192
41. Koomans H.A., Braam B., Geers A.B., Roos J.C., Dorhout Mees E.J. The importance of plasma protein for blood volume and blood pressure homeostasis. Kidney Int. 30:1986;730-735
42. Levick J.R. Capillary filtration-absorption balance reconsidered in light of dynamic extravascular factors. Exp Physiol. 76:1991;825-857. Erratum in: Exp Physiol 1992; 77: 403
43. Lewis D.M., Tooke J.E., Beaman M., Gamble J., Shore A.C. Peripheral microvascular parameters in the nephrotic syndrome. Kidney Int. 54:1998;1261-1266
44. Starling E.H. On the absorption of fluids from the connective tissue spaces. J Physiol (London). 19:1896;312-316
45. Joles J.A., Koomans H.A., Kortlandt W., Boer P., Dorhout Mees E.J. Hypoproteinemia and recovery from edema in dogs. Am J Physiol. 254:1988;F887-F894
46. Koomans H.A., Kortlandt W., Geers A.B., Dorhout Mees E.J. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery. Nephron. 40:1985;391-395
47. Fauchald P., Noddeland H., Norseth J. An evaluation of ultrafiltration as treatment of diuretic-resistant oedema in nephrotic syndrome. Acta Med Scand. 217:1985;127-131
48. Wiig H., Reed R.K. Interstitial compliance and transcapillary Starling pressures in cat skin and skeletal muscle. Am J Physiol. 248:1985;H666-H673
49. Noddeland H., Riisnes S.M., Fadnes H.O. Interstitial fluid colloid osmotic and hydrostatic pressures in subcutaneous tissue of patients with nephrotic syndrome. Scand J Clin Lab Invest. 42:1982;139-146
50. Schnittler H.J. Structural and functional aspects of intercellular junctions in vascular endothelium. Basic Res Cardiol. 93:1998;30-39
51. Yuan S.Y., Ustinova E.E., Wu M.H., Tinsley J.H., Xu W., Korompai F.L., et al. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res. 87:2000;412-417
52. Clarke H., Soler A.P., Mullin J.M. Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets. J Cell Sci. 113:2000;3187-3196
53. Suranyi M.G., Guasch A., Hall B.M., Myers B.D. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis. 21:1993;251-259
54. Ferro T., Neumann P., Gertzberg N., Clements R., Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 278:2000;L1107-L1117
55. Huxley V.H., Tucker V.L., Verburg K.M., Freeman R.H. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res. 60:1987;304-307
56. 2+]i. Am J Physiol. 265:1993;H74-82
57. Rostoker G., Behar A., Lagrue G. Vascular hyperpermeability in nephrotic edema. Nephron. 85:2000;194-200
58. Lagrue G., Xheneumont S., Branellec A., Hirbec G., Weil B. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine. 23:1975;37-40
59. Maruyama K., Tomizawa S., Seki Y., Arai H., Kuroume T. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome. Nephron. 62:1992;27-30
60. Matsumoto K., Ohi H., Kanmatsuse K. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron. 82:1999;32-38
61. Avasthi P.S. Effects of aminonucleoside on rat blood-peritoneal barrier permeability. J Lab Clin Med. 94:1979;295-302
62. Reid C.J., Marsh M.J., Murdoch I.M., Clark G. Nephrotic syndrome in childhood complicated by life threatening pulmonary edema. BMJ. 312:1996;36-38
63. Arnold W.C. Efficacy of metolazone and furosemide in children with furosemide-resistant edema. Pediatrics. 74:1984;872-875
64. Gonzalez-Martin G., Bravo I., Ibarra N., Arancibia A. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. Int J Clin Pharmacol Ther Toxicol. 21:1983;598-601
65. Prandota J. Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediatr Res. 17:1983;141-147
66. Kirchner K.A., Voelker J.R., Brater D.C. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int. 40:1991;418-424
67. Agarwal R., Gorski J.C., Sundblad K., Brater D.C. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol. 11:2000;1100-1105
68. Shapiro M.D., Hasbargen J., Hensen J., Schrier R.W. Role of aldosterone in the sodium retention of patients with nephrotic syndrome. Am J Nephrol. 10:1990;44-48
69. Russo R., Schena F.P., Colombo Pirola L. Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome. Clin Ter. 109:1984;23-29
70. Schapel G.J., Edwards D.G., Robinson J. Potassium-sparing effect of amiloride in a diuretic factorial study in man. Clin Exp Pharmacol Physiol. 2:1975;277-287
71. Monova D., Belovezhdov N. A clinico-therapeutic study of the Bulgarian preparation fupiram. Vutr Boles. 30:1991;45-48
72. Geers A.B., Koomans H.A., Roos J.C., Dorhout Mees E.J. Preservation of blood volume during edema removal in nephrotic subjects. Kidney Int. 28:1985;652-657